Biotechnology - Antibiotics and Infectious diseases

Filter

Popular Filters

1 to 25 of 48 results

Motif Bio to list on AIM to progress novel antibiotic

Motif Bio to list on AIM to progress novel antibiotic

02-02-2015

Motif Bio has announced its intention to list on the alternative Investment Market to raise at least…

Antibiotics and Infectious diseasesBiotechnologyFinancialMotif BiosciencesUK

Holger Zimmermann replaces founding chief executive of AiCuris

Holger Zimmermann replaces founding chief executive of AiCuris

21-01-2015

AiCuris, a company formed by experts from Bayer's virology and bacteriology research divisions, is to…

AiCurisAntibiotics and Infectious diseasesBiotechnologyBoardroomGermany

Motif Biosciences agrees to merge with company holding IP to potential MRSA antibiotic

Motif Biosciences agrees to merge with company holding IP to potential MRSA antibiotic

19-01-2015

Motif Biosciences, a partner of life science business developer Amphion Innovations, has entered into…

Amphion InnovationsAntibiotics and Infectious diseasesBiotechnologyMergers & AcquisitionsMotif BiosciencesMRSA antibioticUSA

Harvoni scores another victory with inclusion on Prime’s preferred list

Harvoni scores another victory with inclusion on Prime’s preferred list

13-01-2015

US pharmacy Prime Therapeutics has agreed to provide hepatitis C drug Harvoni (ledipasvir/sofosbuvir)…

Antibiotics and Infectious diseasesBiotechnologyGileadHarvoniPricingUSA

Cempra announces positive results from Phase III trial of solithromycin in bacterial pneumonia

Cempra announces positive results from Phase III trial of solithromycin in bacterial pneumonia

05-01-2015

Antibiotic specialist Cempra has announced positive top-line results from its pivotal Phase III trial…

Antibiotics and Infectious diseasesBiotechnologyCempraResearchsolithromycinUSA

Phylogica inks $142 million license deal with Genentech

Phylogica inks $142 million license deal with Genentech

22-12-2014

Australian drug discovery firm Phylogica has extended its collaboration with Genentech, the biotech subsidiary…

Antibiotics and Infectious diseasesAustraliaBiotechnologyGenentechLicensingPhylogicaResearchRoche

Emergent BioSolutions acquires EV-035 series of molecules from Evolva Holding

Emergent BioSolutions acquires EV-035 series of molecules from Evolva Holding

17-12-2014

Biopharma company Emergent BioSolutions has acquired the EV-035 series of molecules from Evolva Holding.

Antibiotics and Infectious diseasesBiotechnologyEmergent BioSolutionsEvolvaLicensingResearchUSA

NetScientific invests in PDS Biotechnology

NetScientific invests in PDS Biotechnology

15-12-2014

UK-based life sciences investor NetScientific has made an undisclosed investment in privately-held US…

Antibiotics and Infectious diseasesBiotechnologyMergers & AcquisitionsNetScientificOncologyPDS BiotechnologyUK

Official: Merck & Co to acquire Cubist for $8.4 billion

Official: Merck & Co to acquire Cubist for $8.4 billion

08-12-2014

Confirming weekend speculation and rumors, US pharma giant Merck & Co this morning said it has entered…

Antibiotics and Infectious diseasesBiotechnologyCubicinCubist PharmaceuticalsMerck & CoMergers & AcquisitionsZerbaxa

Micreos' Staphefekt is the world's first bacteria-killing enzyme for human use in MRSA

Micreos' Staphefekt is the world's first bacteria-killing enzyme for human use in MRSA

07-11-2014

The breakthrough achieved by Dutch bacterial specialist Micreos is the most promising development the…

Antibiotics and Infectious diseasesBiosimilarsBiotechnologyInterviewsMicreosNetherlandsResearchStaphefekt

Janssen commits $200 million to speeding up Ebola vaccine development and increasing production

Janssen commits $200 million to speeding up Ebola vaccine development and increasing production

22-10-2014

US health care giant Johnson & Johnson is to commit up to $200 million to accelerate and expand the production…

Antibiotics and Infectious diseasesBavarian NordicBiotechnologyEuropeJanssenResearch

ZMapp Ebola medication will improve public understanding of drug production, says Kalorama

ZMapp Ebola medication will improve public understanding of drug production, says Kalorama

20-10-2014

Mapp Biopharma’s ZMapp Ebola therapy will enhance public understanding of the drug development process,…

Antibiotics and Infectious diseasesBiotechnologyMapp BiopharmaceuticalResearchUSAZMapp

Amgen working on alternative methods for Mapp's Ebola vaccine; Canada sends vaccine vials to WHO

Amgen working on alternative methods for Mapp's Ebola vaccine; Canada sends vaccine vials to WHO

20-10-2014

USA-based Amgen, the world’s leading independent biotech firm, has indicated that it plans to work…

AmgenAntibiotics and Infectious diseasesBiotechnologyCanadaHuman InterestProductionRegulationResearchUSAZMapp

Smith & Nephew shares fall as HP802-247 living cell spray-on therapy fails to meet primary endpoint

Smith & Nephew shares fall as HP802-247 living cell spray-on therapy fails to meet primary endpoint

14-10-2014

Global medical technology business Smith & Nephew has found its Phase III study of HP802-247, a living…

Antibiotics and Infectious diseasesBiotechnologyHP802-247ResearchSmith & NephewUK

EPIC Biotech conference: essential to prove comercial viability of propositions

EPIC Biotech conference: essential to prove comercial viability of propositions

03-10-2014

The key message from European Partnering and Investment Conference in biotech, held yesterday in London,…

Antibiotics and Infectious diseasesBiotechnologyBoehringer IngelheimCardio-vascularCNS DiseasesFinancialJohnson & JohnsonMerck SeronoOncologyResearch

FDA fast track designation for AstraZeneca’s MEDI3902

FDA fast track designation for AstraZeneca’s MEDI3902

24-09-2014

Anglo-Swedish pharma major AstraZeneca’s global biologics R&D arm, MedImmune has received fast track…

Antibiotics and Infectious diseasesAstraZenecaBiotechnologyMEDI3902MedImmuneRegulationUSA

Merck Serono to partner with Lupin for emerging market exposure

Merck Serono to partner with Lupin for emerging market exposure

17-09-2014

Merck Serono, the biotech unit of Germany’s Merck KGaA, has entered a strategic partnership with Indian…

Antibiotics and Infectious diseasesBiotechnologyCardio-vascularDiabetesGermanyIndiaLicensingLupinMerck KGaAMerck Serono

Cubist Pharmaceuticals voluntarily recalls Cubicin lots in the USA

Cubist Pharmaceuticals voluntarily recalls Cubicin lots in the USA

06-08-2014

American biopharmaceutical company Cubist has issued a voluntary recall of certain lots of Cubicin (daptomycin…

Antibiotics and Infectious diseasesBiotechnologyCubicinCubist PharmaceuticalsPhlebitisRegulationThromboembolismUSA

Artes and Burnet Institute collaborate to develop PATH-funded malaria vaccine

Artes and Burnet Institute collaborate to develop PATH-funded malaria vaccine

29-07-2014

German biotechnology company Artes and Australian non-profit virology and communicable disease center…

Antibiotics and Infectious diseasesARTES BiotechnologyAustraliaBiotechnologyDavid AndersonDeputy directorGermanyMalariaMedicineResearch

Antiviral gel in condoms to kill HIV approved in Australia

Antiviral gel in condoms to kill HIV approved in Australia

28-07-2014

Australian biotech firm Starpharma says it has achieved a major milestone with the receipt of Conformity…

AnsellAnti-viralsAntibiotics and Infectious diseasesAustraliaBiotechnologyRegulationStarpharmaVivaGel

ICBA adopts antimicrobial resistance as an inaugural priority, proposed by BIA

ICBA adopts antimicrobial resistance as an inaugural priority, proposed by BIA

27-06-2014

At the inaugural meeting of the newly formed International Council of Biotech Associations (ICBA) which…

Antibiotics and Infectious diseasesBiotechnologyGlobalHealthcareResearch

Debiopharm signs deal with Nobelex Biotech over antibiotics

Debiopharm signs deal with Nobelex Biotech over antibiotics

27-06-2014

Swiss pharma company Debiopharm Group and Canadian biotech company Nobelex Biotech have announced a collaboration…

Antibiotics and Infectious diseasesBiotechnologyCanadaDebiopharmLicensingNobelex Biotech

Helperby Therapeutics and Cadila make progress on first antibiotic resistance breaker

Helperby Therapeutics and Cadila make progress on first antibiotic resistance breaker

19-06-2014

Helperby Therapeutics, a spin-out drug discovery company from St George’s University of London, UK,…

Antibiotic resistanceAntibioticsAntibiotics and Infectious diseasesBiotechnologyCadila PharmaceuticalsHelperby TherapeuticsIndiaUK

BioVersys links with GSK and others to develop preclinical candidates in tuberculosis

27-05-2014

Privately-held Swiss biotech company BioVersys has entered a collaboration with UK pharma giant GlaxoSmithKline…

Antibiotics and Infectious diseasesBiotechnologyBioVersysGlaxoSmithKlineResearchWELLCOME TRUST

1 to 25 of 48 results

COMPANY SPOTLIGHT

Menarini

Back to top